Presented at #ADASciSessions:
In a phase 3 trial involving adults with obesity but without diabetes, the glucagon receptor–GLP-1 receptor dual agonist survodutide led to significantly greater reductions in body weight than placebo. Full SYNCHRONIZE-1 trial results: https://t.co/N2C5YOBnpn
@ADA_DiabetesPro